RESUMEN
Although cross-sectional studies have shown a positive association between Se and cholesterol concentrations, a recent randomised controlled trial in 501 elderly UK individuals of relatively low-Se status found that Se supplementation for 6 months lowered total plasma cholesterol. The Danish PRECISE (PREvention of Cancer by Intervention with Selenium) pilot study (ClinicalTrials.gov ID: NCT01819649) was a 5-year randomised, double-blinded, placebo-controlled trial with four groups (allocation ratio 1:1:1:1). Men and women aged 60-74 years (n 491) were randomised to 100 (n 124), 200 (n 122) or 300 (n 119) µg Se-enriched yeast or matching placebo-yeast tablets (n 126) daily for 5 years. A total of 468 participants continued the study for 6 months and 361 participants, equally distributed across treatment groups, continued for 5 years. Plasma samples were analysed for total and HDL-cholesterol and for total Se concentrations at baseline, 6 months and 5 years. The effect of different doses of Se supplementation on plasma lipid and Se concentrations was estimated by using linear mixed models. Plasma Se concentration increased significantly and dose-dependently in the intervention groups after 6 months and 5 years. Total cholesterol decreased significantly both in the intervention groups and in the placebo group after 6 months and 5 years, with small and nonsignificant differences in changes in plasma concentration of total cholesterol, HDL-cholesterol, non-HDL-cholesterol and total:HDL-cholesterol ratio between intervention and placebo groups. The effect of long-term supplementation with Se on plasma cholesterol concentrations or its sub-fractions did not differ significantly from placebo in this elderly population.
Asunto(s)
Anticolesterolemiantes/uso terapéutico , Enfermedades Cardiovasculares/prevención & control , Colesterol/sangre , Enfermedades Carenciales/dietoterapia , Suplementos Dietéticos , Fenómenos Fisiológicos Nutricionales del Anciano , Selenio/uso terapéutico , Anciano , Anticolesterolemiantes/administración & dosificación , Anticolesterolemiantes/efectos adversos , Anticolesterolemiantes/sangre , Enfermedades Cardiovasculares/etiología , Estudios Transversales , Enfermedades Carenciales/sangre , Enfermedades Carenciales/fisiopatología , Dinamarca/epidemiología , Suplementos Dietéticos/efectos adversos , Método Doble Ciego , Estudios de Factibilidad , Femenino , Humanos , Análisis de Intención de Tratar , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Pacientes Desistentes del Tratamiento , Factores de Riesgo , Selenio/efectos adversos , Selenio/sangre , Selenio/deficiencia , Factores de Tiempo , Levadura Seca/efectos adversos , Levadura Seca/químicaRESUMEN
BACKGROUND: Graves' hyperthyroidism is an autoimmune disease causing hyperfunction of the thyroid gland. The concentration of selenium is high in the thyroid gland and two important groups of enzymes within the thyroid are selenoproteins, that is, they depend on selenium. Selenium may have beneficial effects on autoimmune hypothyroidism and on Graves' orbitopathy, but the effects of selenium on Graves' hyperthyroidism is unknown.We hypothesize that adjuvant selenium may be beneficial in the treatment of Graves' hyperthyroidism. The objective is to investigate if selenium supplementation plus standard treatment with anti-thyroid drugs versus standard treatment with anti-thyroid drugs will lead to a decrease in anti-thyroid drug treatment failure (that is, failure to remain euthyroid, without further treatment, one year after cessation of anti-thyroid drug treatment), faster and longer lasting remission (that is, anti-thyroid drug treatment success), and improved quality of life in patients with Graves' hyperthyroidism. METHODS AND DESIGN: The trial is an investigator-initiated, randomised, blinded, multicentre clinical trial. Inclusion criteria are: age 18 years or older; diagnosis of active Graves' hyperthyroidism within the last two months; and informed consent. Exclusion criteria are major co-morbidity; previous radioactive iodine treatment; ongoing anti-thyroid drug treatment for more than two months; treatment with immunomodulatory drugs; known allergy towards the components in the selenium and placebo pills; pregnancy or breast-feeding; and intake of selenium supplementation above 70 µg per day. We plan to include 492 participants, randomised (1:1) to two tablets of 100 µg selenium once daily for the 24 to 30 months intervention period versus two identical placebo tablets once daily.The primary outcome is the proportion of participants with anti-thyroid drug treatment failure (see above) at the end of the intervention period (24 to 30 months). Secondary outcomes are: thyroid-specific quality of life during the first year after randomisation; level of thyroid stimulating hormone-receptor antibodies at 18 months after randomisation and at the end of the intervention period (24 to 30 months); hyperthyroid symptoms during the first year after randomisation; eye symptoms during the first year after randomisation, and at the end of the intervention period (24 to 30 months); adverse reactions during the intervention period; and serious adverse events during the intervention period. DISCUSSION: It was of great importance to the initiators of this trial, that the results would be directly applicable to daily clinical practice. Therefore, it was designed as a pragmatic trial: the patients follow their usual treatment at their usual hospitals. In order to still collect high quality data on the clinical course and quality of life, an elaborate trial management system was designed to keep track of patient input, need for trial personnel input and action, and to collect data from medical chart systems. Meticulous follow-up on missing responses to the QoL measurements has been incorporated into the system, to minimise missing quality of life data. Monitoring of adverse reactions and events is achieved by thorough instruction of the participants, surveillance of patient-reported outcomes, and integration with national databases regarding hospitalizations. A very long intervention period was necessary, since patients are not considered in remission until one year after stopping anti-thyroid drugs. Usually, patients are treated for 12 to 18 months with anti-thyroid drugs, yielding a total intervention period of 24 to 30 months. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01611896.
Asunto(s)
Antitiroideos/uso terapéutico , Suplementos Dietéticos , Enfermedad de Graves/terapia , Proyectos de Investigación , Selenometionina/metabolismo , Levadura Seca/uso terapéutico , Antitiroideos/efectos adversos , Protocolos Clínicos , Dinamarca , Suplementos Dietéticos/efectos adversos , Enfermedad de Graves/complicaciones , Enfermedad de Graves/diagnóstico , Enfermedad de Graves/tratamiento farmacológico , Humanos , Selección de Paciente , Calidad de Vida , Factores de Tiempo , Resultado del Tratamiento , Levadura Seca/efectos adversos , Levadura Seca/metabolismoRESUMEN
BACKGROUND: The common cold has a profound impact on employee attendance and productivity. Seasonal influenza is responsible for approximately 200,000 hospitalizations and 36,000 deaths per year in the United States alone. Over-the-counter medication efficacy has been questioned, and seasonal vaccination compliance issues abound. Our previously reported randomized trial of an oral fermentation product found an adjuvant benefit for vaccinated individuals in terms of a significantly reduced incidence and duration of cold and flu-like symptoms. METHODS: A concurrent 12-week, randomized, double-blind, placebo-controlled clinical trial of 116 subjects with no recent history of seasonal influenza vaccination was conducted. Participants received once-daily supplementation with 500 mg of a dried modified Saccharomyces cerevisiae oral fermentate (EpiCor) or placebo. Clinical outcome measurements included periodic interval-based in-clinic examinations and serologic analysis at baseline, 6 weeks, and 12 weeks. Participants utilized a standardized self-report symptom diary. RESULTS: Subjects receiving the intervention experienced a statistically significant reduction in the incidence (p = 0.01), a nonsignificant reduction in duration (p = 0.10), and no impact on the severity (p = 0.90) of colds or flu-like symptoms, but a more favorable safety profile compared with subjects receiving placebo. CONCLUSIONS: This nutritional-based fermentate appeared to be safe and efficacious in a unique at-risk population and should receive more clinical research as a potential method to reduce the incidence of cold and flu-like symptoms, in individuals with and without a history of influenza vaccination.
Asunto(s)
Adyuvantes Inmunológicos/uso terapéutico , Antivirales/uso terapéutico , Resfriado Común/tratamiento farmacológico , Gripe Humana/tratamiento farmacológico , Levadura Seca/uso terapéutico , Adyuvantes Inmunológicos/efectos adversos , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Antivirales/efectos adversos , Productos Biológicos/efectos adversos , Productos Biológicos/uso terapéutico , Resfriado Común/epidemiología , Método Doble Ciego , Femenino , Fermentación , Humanos , Incidencia , Vacunas contra la Influenza , Gripe Humana/epidemiología , Masculino , Persona de Mediana Edad , Vacunación , Levadura Seca/efectos adversos , Adulto JovenRESUMEN
The waste tea fungal biomass produced during black tea fermentation was investigated as a dietary ingredient in poultry feeds. A small portion of fungal mat was used as starter culture for the next cycle while the major portion is discarded as waste. Hence a trial study was carried out to utilize the waste fungal biomass as a supplementary diet for broiler chicks. The fungal biomass contained 179.38 g of crude protein, 120 g crude fibre, 4.82 g phosphorus, 6.56 g of calcium and 8.92 MJ metabolizable energy per kilogram of biomass. The dried tea fungus showed phytase activity of 23 IU/mg protein. The supplementation of tea fungal inclusion (TFI) at 150 g/kg concentration in poultry feed increased the feed consumption, body weight, performance efficiency factor (PEF) and the carcass characters of test broilers significantly (P=0.01) over the control. The histopathological examination of liver showed no abnormalities and the mortality rate was zero.
Asunto(s)
Alimentación Animal/microbiología , Peso Corporal/efectos de los fármacos , Pollos/fisiología , Conducta Alimentaria/efectos de los fármacos , Probióticos/administración & dosificación , Té/microbiología , Levadura Seca/administración & dosificación , Animales , Residuos Industriales/prevención & control , Hígado/efectos de los fármacos , Probióticos/efectos adversos , Levadura Seca/efectos adversosRESUMEN
Numerous plant species are used to treat ailments associated with pyrexia in the indigenous health care delivery system of Ethiopia. Notable among these are Ocimum suave and Ocimum lamiifolium. The objective of the present study was thus to evaluate the antipyretic effects of the aqueous and ethanol extracts of the leaves of Ocimum suave and Ocimum lamiifolium in mice. Rectal temperatures were recorded before and after inducing pyrexia as well as after administration of the respective extracts every half an hour for 3h. Parallel experiments were run with a standard antipyretic (acetylsalicylic acid) and the vehicle (distilled water). All the plant extracts showed antipyretic property with reasonable onset and duration of action. Both ethanol and aqueous extracts of Ocimum suave were observed to be more potent than those of Ocimum lamiifolium. Aqueous extract of Ocimum suave and ethanol extract of Ocimum lamiifolium were more potent than their other counterpart extracts. Time dependent antipyretic effect was also observed with some extracts; reduced with time with aqueous extract of Ocimum suave and increased with time with both extracts of Ocimum lamiifolium.
Asunto(s)
Analgésicos no Narcóticos/farmacocinética , Fiebre/inducido químicamente , Fiebre/tratamiento farmacológico , Ocimum , Fitoterapia , Extractos Vegetales/química , Extractos Vegetales/farmacocinética , Hojas de la Planta/química , Levadura Seca/efectos adversos , Administración Oral , Analgésicos no Narcóticos/administración & dosificación , Animales , Temperatura Corporal/efectos de los fármacos , Etanol , Etiopía , Ratones , Plantas Medicinales , Agua , Levadura Seca/administración & dosificaciónRESUMEN
60 migraine patients completed elimination diets after a 5-day period of withdrawal from their normal diet. 52 (87%) of these patients had been using oral contraceptive steroids, tobacco, and/or ergotamine for an average of 3 years, 22 years, and 7.4 years respectively. The commonest foods causing reactions were wheat (78%), orange (65%), eggs (45%), tea and coffee (40% each), chocolate and milk (37%) each), beef (35%), and corn, cane sugar, and yeast (33% each). When an average of ten common foods were avoided there was a dramatic fall in the number of headaches per month, 85% of patients becoming headache-free. The 25% of patients with hypertension became normotensive. Chemicals in the home environment can make this testing difficult for outpatients. Both immunological and non-immunological mechanisms may play a part in the pathogenesis of migraine caused by food intolerance.
Asunto(s)
Alérgenos/administración & dosificación , Hipersensibilidad a los Alimentos/complicaciones , Trastornos Migrañosos/etiología , Adolescente , Adulto , Animales , Cacao/efectos adversos , Carbohidratos/efectos adversos , Bovinos , Café/efectos adversos , Huevos/efectos adversos , Femenino , Frutas/efectos adversos , Humanos , Masculino , Carne/efectos adversos , Persona de Mediana Edad , Trastornos Migrañosos/dietoterapia , Leche/efectos adversos , Té/efectos adversos , Triticum/efectos adversos , Levadura Seca/efectos adversos , Zea mays/efectos adversosRESUMEN
Many foods and medications containing hidden ingredients are described; labelling is usually incomplete and often misleading. Patients sensitive to foods and chemicals are advised to read and interpret labels. Consumers, manufacturers, government agencies and allergists should cooperate to ensure an adequate national food supply without unduly jeopardizing an increasingly sensitive population.